Cystinosis Forecast Markets 2017-2027 - USA, Canada, France, Germany, Italy, Spain, UK, Poland, Austria, Netherlands, Ireland, Turkey, Japan, South Korea, India, Australia, Brazil, Mexico, Argentina

Dublin, Jan. 15, 2018 -- The "Cystinosis Forecast in 19 Major Markets 2017-2027" report has been added to ResearchAndMarkets.com's offering.

This report provides the current prevalent population for cystinosis across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Austria, The Netherlands, Ireland, Turkey, Japan, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Cystinosis is a rare inherited lysosomal storage disorder caused by mutations in the CTNS gene that encodes cystinosin, a lysosomal cystine-proton co-transporter. This results in an abnormal accumulation of the amino acid cystine within the lysosomes of all body cells and tissues. Although it is a monogenic, autosomal recessive disease, there are three clinical presentations of cystinosis based on the age at diagnosis and the magnitude of cellular cystine deposition.

Providing a value-added level of insight, the three clinical presentations of cystinosis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Reasons to Buy:

• Able to quantify patient populations in global cystinosis market to target the development of future products, pricing strategies and launch plans
• Gain further insight into the prevalence of the subdivided types of cystinosis and identify patient segments with high potential
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries
• Provide a level of understanding on the impact from specific clinical presentations of the disease on cystinosis prevalent population
• Identify sub-populations within cystinosis which require treatment
• Gain an understanding of the specific markets that have the largest number of cystinosis patients

Key Topics Covered:

1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key Comorbid Conditions / Features Associated With the Disease
8. Methodology for Quantification of Patient Numbers
9. Top-Line Prevalence for Cystinosis
10. Types of Cystinosis in Patients
11. Abbreviations Used in the Report
12. Other Publications
13. Online Patient-Based Databases
14. Patient-Based Offering
15. Online Pricing Data & Platforms
16. References
17. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/qkgp39/cystinosis?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Endocrine and Metabolic Disorders Drugs